Tatva Chintan Pharma Chem IPO - Diversified Portfolio, Expansion Plan To Drive Profitability: ICICI Direct
A volumetric flask, containing chemical solution sits in a laboratory. (Photographer Dhiraj Singh/Bloomberg)

Tatva Chintan Pharma Chem IPO - Diversified Portfolio, Expansion Plan To Drive Profitability: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Incorporated in 1996, Tatva Chintan Pharma Chem Ltd. is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals.

Apart from customers in India, the company also exports products to over 25 countries, including the U.S., China, Germany, Japan, South Africa, and the UK.

As on March 31, 2021, it manufactured over 154 products.

The company intends to further diversify into products with prospects for increased growth and profitability.

Click on the attachment to read the full report:

ICICI Direct Tatva Chintan Pharma IPO Review.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.